SEC Filings
Phathom Pharmaceuticals’ Finance Vice President To Leave December 4
Robert Breedlove will keep his finance and accounting roles until his departure, which Phathom said was unrelated to a disagreement.
Phathom Pharmaceuticals (PHAT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Robert Breedlove will keep his finance and accounting roles until his departure, which Phathom said was unrelated to a disagreement.
SEC Filings
James Topper's 6,013,327 shares equal 7.4% of Phathom, the latest amendment to the Frazier group's ownership statement shows.
Earnings
CEO Steve Basta says Phathom has intervened in BDR Pharmaceuticals' suit and will defend its position "vigorously."
Earnings
Phathom's CEO says doctors are stuck in habit, so a $0 copay is offered only through BlinkRx, with benefits building over several quarters.
SEC Filings
The cash floor on Phathom's royalty financing rose from $30 million on October 1, while generic-drug filers challenge its exclusivity.
SEC Filings
The heartburn-drug maker posted a second straight quarter of positive operating cash flow and held its full-year revenue forecast of $310 million to $325 million.
SEC Filings
Comments are due November 23, and a second purported generic filer has surfaced in the lawsuit over the heartburn drug's exclusivity.
SEC Filings
The generic drugmaker says the agency wrongly stretched protection for the heartburn drug; Phathom says the FDA got it right.